Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 6Unknown 4Active not recruiting 4Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 14Lung Neoplasms 6Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Pancreatic Neoplasms 3Colorectal Neoplasms 3Urinary Bladder Neoplasms 2Carcinoma, Renal Cell 2Uveal Melanoma 1Squamous Non-small Cell Lung Cancer 1Small Cell Lung Carcinoma 1Primary Myelofibrosis 1Polycythemia Vera 1Oropharyngeal Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Microsatellite Instability 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large B-Cell, Diffuse 1Liver Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Breast Cancer Female 1Biliary Tract Neoplasms 1Adenocarcinoma of Lung 1Adenocarcinoma Of Esophagus 1

Interventions

Nivolumab 17Ipilimumab 14pembrolizumab 11Cyclophosphamide 8trametinib 7dabrafenib 6Interleukin-2 6aldesleukin 5Vemurafenib 5Radiotherapy 5sargramostim 4130-nm albumin-bound paclitaxel 4fludarabine 3encorafenib 3binimetinib 3Specimen Handling 3Radiosurgery 3Melphalan 3Granulocyte-Macrophage Colony-Stimulating Factor 3fludarabine phosphate 2Magnetic Resonance Spectroscopy 2Introns 2Infliximab 2Celecoxib 2CTLA-4 Antigen 2Biopsy 2Bevacizumab 2Albumin-Bound Paclitaxel 2yeast-CEA vaccine 1vitespin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Melanoma × durvalumab × Clear all
NCT04223648 2021-11-22

Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma

Yale University

Phase EARLY_PHASE1 Withdrawn
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡